Handelsbanken Fonder
UTHR icon

Handelsbanken Fonder’s United Therapeutics UTHR Stock Holding History

Handelsbanken Fonder’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.11M Buy
13,120
+520
+4% +$293K 0.02% 431
2026
Q1 		$7.47M Hold
12,600
– – 0.02% 412
2025
Q4 		$6.14M Buy
12,600
+1,700
+16% +$792K 0.02% 454
2025
Q3 		$4.57M Hold
10,900
– – 0.01% 495
2025
Q2 		$3.13M Sell
10,900
-200
-2% -$59.8K 0.01% 519
2025
Q1 		$3.42M Hold
11,100
– – 0.01% 506
2024
Q4 		$3.92M Sell
11,100
-1,900
-15% -$698K 0.02% 480
2024
Q3 		$4.66M Buy
13,000
+2,200
+20% +$743K 0.02% 443
2024
Q2 		$3.44M Sell
10,800
-900
-8% -$238K 0.02% 467
2024
Q1 		$2.69M Buy
11,700
+3,100
+36% +$700K 0.01% 538
2023
Q4 		$1.89M Buy
8,600
+700
+9% +$161K 0.01% 571
2023
Q3 		$1.78M Buy
7,900
+600
+8% +$138K 0.01% 567
2023
Q2 		$1.61M Hold
7,300
– – 0.01% 589
2023
Q1 		$1.64M Buy
7,300
+1,400
+24% +$345K 0.01% 571
2022
Q4 		$1.64M Hold
5,900
– – 0.01% 544
2022
Q3 		$1.24M Hold
5,900
– – 0.01% 598
2022
Q2 		$1.39M Sell
5,900
-800
-12% -$163K 0.01% 599
2022
Q1 		$1.2M Hold
6,700
– – 0.01% 723
2021
Q4 		$1.45M Sell
6,700
-2,600
-28% -$510K 0.01% 727
2021
Q3 		$1.72M Buy
9,300
+1,800
+24% +$355K 0.01% 666
2021
Q2 		$1.35M Sell
7,500
-800
-10% -$152K 0.01% 772
2021
Q1 		$1.39M Hold
8,300
– – 0.01% 711
2020
Q4 		$1.26M Buy
8,300
+1,500
+22% +$197K 0.01% 731
2020
Q3 		$687K Hold
6,800
– – 0.01% 845
2020
Q2 		$823K Buy
+6,800
New +$765K 0.01% 761
2016
Q1 		– Sell
-7,005
Closed -$1.1M – 570
2015
Q4 		$1.1M Buy
+7,005
New +$1.02M 0.02% 475

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Handelsbanken Fonder's UTHR Position: Q2 2026 in Review

Handelsbanken Fonder increased its United Therapeutics (UTHR) stake by 4.1% in Q2 2026, buying an estimated $293K and bringing the position to 13,120 shares worth $7.11M. The position accounts for 0.02% of the portfolio, ranked #431.

Handelsbanken Fonder first reported a position in UTHR in Q4 2015 and has held it in 26 quarters since. The position peaked at $7.47M in Q1 2026. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Handelsbanken Fonder held 13,120 shares of United Therapeutics worth $7.11M as of Q2 2026.
  • Handelsbanken Fonder bought 520 United Therapeutics shares in Q2 2026, an estimated $293K.
  • United Therapeutics made up 0.02% of Handelsbanken Fonder's portfolio in Q2 2026, its #431 holding.
  • Handelsbanken Fonder first reported a position in United Therapeutics in Q4 2015 and has held it in 26 quarters since.
  • Handelsbanken Fonder's United Therapeutics position peaked at $7.47M in Q1 2026.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.